State Street Corp Acurx Pharmaceuticals, Inc. Call Options Transaction History
State Street Corp
- $2.36 Trillion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ACXP
# of Institutions
27Shares Held
3.49MCall Options Held
100Put Options Held
0-
Sabby Management, LLC Upper Saddle River, NJ2.04MShares$981,3826.36% of portfolio
-
Vanguard Group Inc Valley Forge, PA529KShares$254,0870.0% of portfolio
-
Prospect Financial Services LLC Melville, NY367KShares$175,9560.08% of portfolio
-
Geode Capital Management, LLC Boston, MA171KShares$82,3130.0% of portfolio
-
Morgan Stanley New York, NY106KShares$50,9760.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $5.55M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...